Oxaliplatin Sandoz

Oxaliplatin, the active ingredient in Oxaliplatin Sandoz, is a platinum-based chemotherapy agent presented as a 100 mg powder for concentrate for solution for infusion use. It treats colorectal cancer and other gastrointestinal malignancies in adult patients. GNH USA supplies Oxaliplatin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oxaliplatin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oxaliplatin is a platinum‑based chemotherapeutic that interferes with DNA synthesis in several gastrointestinal cancers.

- Colorectal cancer: enhances tumor response when combined with fluoropyrimidine‑based regimens. - Gastric cancer: used in combination protocols for advanced disease. - Pancreatic cancer: contributes to disease control as part of multi‑drug regimens.

Oxaliplatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Peripheral neuropathy: tingling or numbness, often dose‑related. - Nausea and vomiting: may require anti‑emetic support. - Diarrhea: can be self‑limiting or require treatment. - Fatigue: generalized tiredness during therapy. - Elevated liver enzymes: mild transaminase rise. - Low blood counts: neutropenia or anemia.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Persistent peripheral neuropathy: long‑lasting sensory deficits. - Acute hemolytic anemia: rare but potentially life‑threatening. - Cardiac arrhythmias: uncommon electrocardiographic changes. - Severe neutropenic infection: febrile neutropenia requiring hospitalization. - Renal impairment: acute kidney injury in susceptible patients.

When using Oxaliplatin, clinicians should observe several safety measures.

- Renal function: assess baseline creatinine and monitor during therapy. - Hepatic function: evaluate liver enzymes before each cycle. - Neuropathy monitoring: conduct regular neurological examinations. - Hematologic monitoring: perform complete blood counts regularly. - Hypersensitivity risk: be prepared to manage infusion reactions. - Store at below 25°C: keep in original container, protect from moisture and light.

Oxaliplatin can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Concurrent use of other platinum agents: increased risk of cumulative toxicity. - High‑dose vitamin C infusions: may reduce platinum‑DNA binding.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): heightened bleeding risk due to thrombocytopenia.\n- Strong CYP450 inducers: potential alteration of supportive‑care drug levels. - Nephrotoxic antibiotics (e.g., aminoglycosides): added renal stress. - Antiemetic regimens containing dopamine antagonists: may potentiate neurotoxicity. - Electrolyte‑altering agents (e.g., loop diuretics): influence neuropathy severity.